Patheon sells clinical packaging business to Bellwyck

Published: 7-Sep-2012
Packaging Regulatory

Part of strategic plan to focus on solid dose and parenteral development and manufacturing


Patheon has sold its global secondary clinical packaging and clinical distribution services business to Bellwyck Packaging Solutions, a private company with 20 years’ experience providing clinical trial and contract services for secondary packaging.

‘We are very happy to have reached an agreement with Bellwyck for this business,’ said James C. Mullen, Patheon's Chief Executive Officer. ‘This transaction is part of our continued focus on our core competencies of solid-dose and parenteral development and manufacturing.’

Patheon's secondary clinical packaging and clinical distribution services business is globally managed from its Burlington, Ontario, Canada facility, and includes an operating presence in Cincinnati, Ohio. Terms of the sale have not been disclosed.

  • Companies:
  • Patheon
  • Bellwyck Packaging Solutions
See more

You may also like

Manufacturing

PCI expands in Canada with clinical trial services acquisition

Read more
Bellwyck Pharma Services has joined US-based PCI’s global network

Trending Articles

  1. Scleroderma treatment by Certa Therapeutics granted US FDA fast track FT011 is a novel, first-in-class oral therapy for the treatment of chronic fibrosis in multiple organs
  2. The key role of IVDs in healthcare: challenges to commercialisation and access In simple terms, in vitro diagnostic (IVD) tests are done on samples such as blood or tissue that have been taken from the human body. IVDs can detect diseases, conditions and infections, provide patients with a better understanding of their ailment and how it might be managed and changed with treatment
  3. Post-Brexit border paperwork and inspections postponed for life sciences sector The six month extension will allow life science companies to the make necessary alterations to their supply chains to accommodate for the novel post-Brexit border paperwork
  4. PCI Pharma Services PCI Pharma Services: Your bridge between life-changing therapies and patients.
  5. AstraZeneca to stop production of Pulmicort pMDI Agreements with SkyePharma expected to be terminated

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

You may also like

Manufacturing

PCI expands in Canada with clinical trial services acquisition

Bellwyck Pharma Services has joined US-based PCI’s global network
Regulatory

Fortress Biotech subsidiary Caelum Biosciences enters biopharmaceutical manufacturing agreement with Patheon

Agreement will support Phase II/III studies of Caelum's CAEL-101 in AL amyloidosis
Regulatory

Patheon outsources most NDAs of any provider

Company held approximately 30% of all outsourced approvals in 2016, four times more than the nearest competitor
Containment

Patheon regulatory expert to present at 2014 PIC/S Annual Seminar

Presentation will showcase Patheon’s strategic plan for manufacturing selective cytostatic tablets at the Bourgoin multiproduct facility
Manufacturing

Patheon launches updated Quick to Clinic programme

Offers customers a 12-week clinical trial programme that delivers maximum speed, but does not compromise quality
Manufacturing

Patheon to expand drug facility in France

Patheon is expanding its manufacturing facility in France to enable it to bring to Europe the same services that it offers from its plants in North America
Packaging

Patheon extends sterile filling capabilities at Swindon

<p>Patheon, a global provider of drug development and manufacturing services to the pharmaceutical industry, has extended its aseptic vial filling capabilities at its Swindon, UK facility to include the commercial supply of small-scale specialist products. </p>
Subscribe now